AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Presentation (Timestamp: 1 Year Prior to Presentation)
A 29-year-old female PhD scholar residing in an Delhi presents to the outpatient clinic for evaluation of a 1-year history of episodic red and purple skin lesions, localized fingertip and toe pain, visual disturbances, and intermittent focal neurological symptoms.
HPI:
- Rash & Digital Pain: Describes recurrent erythematous blanchable macules and non-palpable purpura on her hands, feet, and ankles occurring several days per week. Associated with constant, throbbing fingertip and toe pain lasting 2–3 days per episode, followed by recurrent nail bed changes.
- Neurological & Visual Symptoms: Reports episodic visual scotomas ("bright flashes/dots of light" lasting 15 minutes) often triggered by exertion or mental stress, followed by headaches. Reports one episode of transient right arm and leg weakness lasting several seconds (TIA).
- Systemic Symptoms: Reports persistent fatigue over 1 year and an unintentional 5 kg (10 lb) weight loss over the past 3 months. Denies fever, chills, night sweats, chest pain, orthopnea, or joint pain.
- PMH & Meds: Migraine headaches, exercise-induced asthma, myopia. Meds: Mirena IUD, Albuterol inhaler PRN.
- Social History: PhD researcher, non-smoker, occasional alcohol, active in outdoor trekking/rock climbing. No recent travel outside India.

Resident:

ERROR from Resident: Network error: [SSL: UNEXPECTED_EOF_WHILE_READING] EOF occurred in violation of protocol (_ssl.c:1032)

Attending:

Hello Attending Consultant here

No Chief Resident plan provided—cannot critique. Proceeding from HPI alone.

Top 3 DDx:
1. Antiphospholipid syndrome (APS; primary or SLE-associated) – livedo/purpura, digital ischemia, migraine/scotoma, TIA, constitutional sx.
2. Cutaneous small-vessel vasculitis (HSV/cryoglobulinemic) with CNS involvement.
3. Sneddon syndrome (livedo + cerebrovascular events).

5 specific points:
- Obtain full APS panel (LA, aCL IgG/M, anti-β2GP1) + ANA/ENA/C3/C4 immediately.
- Document lesion morphology with photos; biopsy purpuric site (H&E + DIF) during active episode.
- Urgent brain MRI/MRA + fundoscopy for scotomas/TIA.
- Quantify digital ischemia (ABI, nailfold capillaroscopy); rule out emboli (echo).
- Screen cryos, SPEP, hepatitis serologies; hold estrogen-IUD pending results.
- Serial neuro checks; ASA 81 mg empiric if no bleed risk.
- Weight-loss workup: CT chest/abd if labs negative.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: A microvascular occlusive syndrome — leading candidate is essential thrombocythemia with erythromelalgia: exertion/stress-triggered burning acral pain with red-purple discoloration, transient scotomas, TIA, fatigue, and weight loss fit platelet-mediated microvascular ischemia in a young woman.

Top differentials:
- Antiphospholipid syndrome (± SLE): fits purpura, digital ischemia, TIA, migraine — but pain is typically not exertion-triggered burning, and lesions here sound livedoid/erythromelalgic rather than thrombotic-ulcerative.
- Fabry disease: acroparesthesias triggered by exertion/stress, angiokeratomas, early TIA/stroke; symptomatic female heterozygotes exist. Nail bed changes and scotomas are less typical.
- Sneddon syndrome / livedoid vasculopathy: livedo + cerebrovascular events, but doesn't explain episodic burning pain or constitutional symptoms.

Key pivot: The trigger pattern — exertion/heat/stress provoking acral pain and visual phenomena — points to microvascular platelet plugging, not migraine with aura or primary vasculitis.

Next move: CBC with smear and platelet count first (cheap, decisive), then JAK2/CALR/MPL testing, APS panel, ANA, ESR/CRP; fundoscopy and MRI brain.

Teaching pearl: Erythromelalgia + transient neurologic/visual symptoms = think myeloproliferative neoplasm; a single platelet count can crack the case.

Round 2

User:

Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 36.8°C, HR 72 bpm, BP 112/70 mmHg, RR 14/min, SpO2 99% room air. BMI 18.5 kg/m² (thin build). Normal fundoscopic exam. Extremities: Splinter hemorrhages noted under 3rd and 4th left fingernail beds. Skin: Erythematous blanchable macules with non-palpable purpura over distal feet and ankles, tender swollen finger pads, and livedo racemosa (mottling) on palms. Normal joint and focal neurological exam.
Initial Laboratory Panel:
- Hemogram: Mild normocytic anemia (Hb 11.4 g/dL, MCV 86 fL), WBC 6.8 x 10³/µL (normal differential, normal absolute eosinophil count), Platelets 220,000/µL.
- Biochemistry & Urinalysis: Normal BMP (Serum Creatinine 0.7 mg/dL), normal LFTs, normal ESR (12 mm/hr), normal CRP (2.1 mg/L), normal urinalysis (no hematuria or proteinuria).
- Serology & Autoimmune Panel: Low-titer ANA positive (1:160, speckled pattern). Negative Rheumatoid Factor, Anti-dsDNA, Anti-Smith, c-ANCA, p-ANCA, Anti-MPO, Anti-PR3. Serologies for HIV 1/2, HBsAg, Anti-HCV, and Syphilis (VDRL) all negative. Blood cultures x 3 negative.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Splinter hemorrhages, tender finger pads (Osler-like), livedo racemosa, TIA history, normocytic anemia, normal platelets (excluding essential thrombocythemia), low-titer ANA (1:160), negative blood cultures and inflammatory markers.

Probability-Based Differential Diagnoses:
1. Culture-Negative Endocarditis / NBTE / Atrial Myxoma (40%): Embolic stigmata (splinter hemorrhages, Janeway/Osler-like nodes, TIA) and weight loss strongly suggest a central embolic source.
2. Antiphospholipid Syndrome / Sneddon Syndrome (30%): Livedo racemosa, TIA, digital ischemic lesions, and mild anemia in a young female.
3. ANCA-Negative Vasculitis (e.g., Polyarteritis Nodosa) (15%): Tender digital nodules, livedo, purpura, and constitutional symptoms.
4. Fabry Disease (15%): Episodic acral pain, livedo, and early transient neuro/visual symptoms in female heterozygotes.

5 Prioritized Next Tests:
1. Transesophageal Echocardiogram (TEE): Rule out marantic vegetations, fastidious IE, or atrial myxoma.
2. Comprehensive Antiphospholipid Panel: Lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I.
3. Skin Punch Biopsy: From active livedo racemosa/purpura for histology and DIF.
4. Brain MRI/MRA: Evaluate microvascular/embolic ischemia.
5. Atypical IE Serologies: Bartonella

Attending:

Hello Attending Consultant here

Critique: Solid shift to embolic source post-normal platelets/ESR; TEE first-line is correct. Overweights PAN (normal CRP/ANCA/UA argue against). Fabry less likely sans angiokeratomas/renal sx. Add complements/cryos; defer atypical serologies until TEE.

Top 3 DDx:
1. APS (primary/Sneddon overlap) – livedo racemosa, splinters, digital ischemia, TIA, low-titer ANA.
2. NBTE/culture-neg IE or atrial myxoma – embolic stigmata + constitutional/anemia.
3. Cryoglobulinemic vasculitis (non-hep) – purpura/livedo + acral pain.

6 points:
- TEE + bubble study STAT (vegetations/myxoma/PFO).
- Full APS panel (LA/aCL/β2GP1 ×2) + C3/C4/cryos now.
- Punch biopsy active livedo (H&E/DIF/thrombi).
- MRI brain + DWI for silent emboli.
- Hold IUD; start ASA 81 mg if APS pending.
- Repeat blood cultures + Bartonella/Coxiella only if TEE +.
- Quantiferon/TB if weight loss persists.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Antiphospholipid syndrome (likely primary, with Sneddon-like phenotype) — livedo racemosa, digital ischemic lesions/splinters, TIA, exertion-triggered scotomas (retinal microvascular), low-titer ANA, anemia, and weight loss. Inflammation is strikingly absent (normal ESR/CRP), favoring thrombotic microangiopathy over vasculitis.

Top differentials:
- NBTE/culture-negative IE or atrial myxoma: splinters + weight loss are classic embolic clues — TEE is mandatory. But no fever/murmur and cultures negative.
- Livedoid vasculopathy: fits livedo + acral purpura but rarely causes TIA/scotomas or constitutional symptoms.
- Cryoglobulinemia: fits purpura/livedo/acral pain, but HCV negative; still test cryos/complements.
- Fabry less likely: normal exam lacks angiokeratomas/corneal changes.

Key pivot: Normal inflammatory markers and platelets convert this from vasculitis/MPN to a non-inflammatory thrombotic/embolic process.

Next move: TEE + full antiphospholipid panel (LA, aCL, anti-β2GP1), complements, cryoglobulins; skin biopsy of livedo; MRI brain with DWI.

Teaching pearl: Livedo racemosa + cerebrovascular events with normal ESR/CRP should immediately trigger an antiphospholipid/embolic workup, not more vasculitis serologies.

Round 3

User:

Stage 3: Multi-Specialty Workup, Skin Biopsy & Initial Imaging (Timestamp: Months 1-12)
Diagnostic Interventions & Initial Testing:
- Skin Biopsy (Right Ankle): Full-thickness dermal biopsy demonstrated sparse perivascular lymphocytic infiltrate and mild dermal edema without evidence of necrotizing vasculitis, leukocytoclasia, or fibrinoid necrosis (reported as non-specific).
- Non-Contrast Brain MRI & Chest X-Ray: Brain MRI showed normal parenchyma without acute ischemic infarcts or demyelination. Chest X-ray showed clear lung fields with subtle left atrial prominence.
- Diagnostic Hypotheses Considered: Systemic Vasculitis (Polyarteritis Nodosa / PAN mimic), Antiphospholipid Syndrome, Degos Disease, Sneddon Syndrome, or Idiopathic Cryoglobulinemia.

Resident:

Hello, Chief Resident here.

Updated Key Findings:
Skin biopsy rules out necrotizing vasculitis. CXR shows left atrial prominence, which, paired with embolic stigmata (splinter hemorrhages, Osler-like nodes), livedo racemosa, transient neuro-visual events, weight loss, and anemia, strongly shifts the diagnosis toward a cardiac embolic etiology.

Probability-Based Differential Diagnoses:
1. Cardiac Atrial Myxoma (60%): High index of suspicion due to left atrial prominence, classic embolic phenomena (splinters, TIA, scotomas), and constitutional symptoms with normal inflammatory markers.
2. Antiphospholipid Syndrome / Sneddon Syndrome (25%): Non-inflammatory thrombotic microangiopathy with livedo racemosa and transient neurological deficits.
3. Non-Bacterial Thrombotic Endocarditis (NBTE) / Marantic Endocarditis (10%): Sterile valvular vegetations causing systemic arterial emboli.
4. Fabry Disease (5%): X-linked storage disorder with acral pain, livedo, and microvascular events.

Prioritized Next Tests:
1. Transthoracic & Transesophageal Echocardiography (TTE/TEE): First-line study to evaluate for left atrial myxoma or occult valvular lesions.
2. Comprehensive Antiphospholipid Antibody Panel: Lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein I.
3. Leukocyte Alpha-Galactosidase A Activity & GLA Sequencing: Rule out Fabry disease.
4. Hypercoagulability Workup: Protein C/S, antithrombin III, Factor V Leiden.

Attending:

Hello Attending Consultant here

Critique: Correct pivot to myxoma given LA prominence + emboli + constitutional sx + non-diagnostic biopsy/normal MRI/ESR. Overweights Fabry (no angiokeratomas/cornea verticillata). APS still viable but secondary to myxoma possible. Defer hypercoag/Fabry until echo; biopsy already excludes Degos/PAN.

Top 3 DDx:
1. Left atrial myxoma – LA prominence, splinters/Osler-like, TIA/scotomas, weight loss/anemia, livedo.
2. APS (primary/Sneddon) – livedo racemosa + cerebral events, non-inflammatory.
3. NBTE – sterile emboli + cachexia (paraneoplastic screen needed).

6 points:
- STAT TTE then TEE (myxoma size/mobility/attachment).
- Full APS panel + C3/C4 now (pre-op).
- Cardiac MRI if TEE equivocal.
- CT chest/abd/pelvis for occult malignancy if NBTE.
- Hold empiric AC until mass characterized (embolus risk).
- Urgent cardio-thoracic consult if myxoma confirmed.
- Serial neuro exams; ASA bridge only if APS+.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Left atrial myxoma — the left atrial prominence on CXR, embolic stigmata (splinter hemorrhages, tender finger pads, livedo, TIA, exertional scotomas), constitutional symptoms (weight loss, anemia), and normal inflammatory markers with a bland skin biopsy form a classic triad: emboli + constitutional illness + cardiac mass.

Top differentials:
- Antiphospholipid syndrome/Sneddon: fits livedo + cerebral events, but doesn't explain LA enlargement or weight loss; still test APS panel.
- NBTE (marantic endocarditis): sterile emboli + cachexia — consider occult malignancy; TEE will distinguish.
- Degos disease: livedo + systemic involvement, but biopsy lacks wedge-shaped necrosis; unlikely.

Key pivot: The left atrial prominence on an otherwise normal workup — a single radiographic clue that reframes "vasculitis mimic" as a cardiac embolic source.

Next move: Urgent TTE followed by TEE to characterize the mass; if myxoma confirmed, prompt cardiothoracic surgical resection (embolization/stroke risk is high). Obtain APS panel and malignancy screen in parallel.

Teaching pearl: The myxoma triad — embolism, constitutional symptoms, and cardiac findings — is a great vasculitis mimic; always image the heart when "vasculitis" has normal ESR/CRP and a bland biopsy.

Round 4

User:

Stage 4: Echocardiography & Cardiac MRI Discovery (Timestamp: Diagnostic Confirmation)
Given persistent embolic splinter hemorrhages, digital vasculopathy, and transient ischemic events, advanced cardiac imaging was requested:
- Transthoracic & Transesophageal Echocardiogram (TTE / TEE): Demonstrates a large 6.0 cm x 3.0 cm mobile, gelatinous, pedunculated left atrial mass attached via a distinct stalk to the fossa ovalis of the interatrial septum, prolapsing across the mitral valve into the left ventricle during diastole and causing intermittent mitral inflow occlusion.
- Cardiac MRI: Confirmed a well-circumscribed, heterogeneously enhancing 6 cm pedunculated left atrial mass anchored to the interatrial septum without myocardial invasion, characteristic of an Atrial Myxoma.

Resident:

Hello, Chief Resident here.

Updated Key Findings: TEE and Cardiac MRI confirm a large (6.0 × 3.0 cm) pedunculated, mobile left atrial mass anchored to the fossa ovalis, causing intermittent mitral inflow occlusion and systemic microembolization.

Probability-Based Diagnoses:
1. Sporadic Left Atrial Myxoma (98%): Pathognomonic cardiac imaging, classic location at fossa ovalis, and full unification of systemic embolization (splinters, TIA, livedo) and constitutional symptoms.
2. Carney Complex / Familial Myxoma (2%): Must be considered in a young patient presenting with primary myxoma.

5 Prioritized Next Steps & Management:
1. Urgent Cardiothoracic Surgery Consult: Prompt surgical resection of the mass to eliminate risks of stroke, systemic embolization, or sudden death from hemodynamic collapse.
2. Histopathological Confirmation: Pathology of the resected tumor to confirm benign atrial myxoma.
3. Screening for Carney Complex: Evaluate for cutaneous lentigines, endocrine hyperfunction (Cushing's, thyroid, pituitary), and order PRKAR1A genetic testing.
4. Family Screening: Baseline screening TTE for first-degree relatives to rule out familial cardiac myxomas.
5. Post-Operative Surveillance: Post-op TTE prior to discharge, followed by annual echocardiograms to monitor for recurrence.

Attending:

Hello Attending Consultant here

Critique: Excellent prioritization of urgent resection; imaging is pathognomonic. Minor gaps: omit routine family TTE unless Carney features; add pre-op APS/coag screen (myxoma can induce APS-like Abs) and avoid empiric AC (embolization risk). Histopathology mandatory for rare mimics (thrombus/sarcoma).

Top 3 DDx:
1. Sporadic left atrial myxoma (definitive by imaging/location).
2. Carney complex-associated myxoma (young female; screen lentigines/endocrine).
3. Atrial thrombus or myxosarcoma (rare; histo distinguishes).

6 points:
- STAT CT surgery consult for resection (CPB, septal excision).
- Pre-op coronary CTA if >40y or risk factors; full APS panel.
- Intra-op TEE for residual/fragmentation; send mass for H&E/IHC.
- Screen Carney: skin exam, cortisol/IGF-1/TSH, PRKAR1A if positive.
- Post-resection TTE predischarge + q6-12mo x5y for recurrence.
- Neuro MRI if new deficits; ASA bridge only post-op if residual risk.
- Genetic counseling if familial features.

Expert:

Hello, Expert Clinician here.

Final unifying diagnosis: Sporadic left atrial myxoma — the imaging is definitive: a pedunculated fossa ovalis mass prolapsing through the mitral valve explains everything: systemic emboli (splinters, digital ischemia, TIA, scotomas), constitutional symptoms (weight loss, anemia), and even exertional triggers (position/exertion-dependent tumor obstruction and embolization). Normal ESR/CRP and bland biopsy were the red herring pointing away from vasculitis.

Residual differentials: Carney complex (screen clinically — lentigines, endocrinopathy, PRKAR1A) and histologic mimics (thrombus, sarcoma) — pathology will settle this.

Key pivot: The left atrial prominence on a routine CXR — an easily missed clue that redirected the entire workup from autoimmune serologies to the heart.

Most important move: Urgent surgical resection — risk of catastrophic stroke or sudden death from mitral obstruction is substantial; do not anticoagulate pre-op (may fragment tumor).

Teaching pearl: Myxoma is the great vasculitis mimic — when "vasculitis" shows livedo, emboli, and constitutional symptoms with normal inflammatory markers and bland biopsy, echo the heart before escalating immunosuppression.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Left Atrial Myxoma presenting with systemic tumor micro-embolization (splinter hemorrhages, digital vasculopathic skin lesions, visual scotomas, transient focal ischemic attacks) and paraneoplastic cytokine release mimicking systemic vasculitis.
Treatment Plan: Urgent cardiothoracic surgery referral for median sternotomy, complete surgical excision of the left atrial myxoma, and reconstruction of the interatrial septum with a pericardial patch.
Outcome: Histopathology confirmed a benign atrial myxoma composed of stellate and globular myxoma cells within an abundant acid mucopolysaccharide stroma. Complete resolution of skin eruptions, splinter hemorrhages, visual scotomas, and constitutional fatigue, with annual echocardiographic surveillance scheduled.

Resident:

Hello, Chief Resident here.

Key Findings & Case Resolution:
Histopathology confirms a benign Left Atrial Myxoma. Successful surgical resection resulted in total resolution of systemic micro-embolic stigmata (splinter hemorrhages, TIA, scotomas, livedo) and paraneoplastic symptoms (fatigue, weight loss).

Final Differential Diagnoses (Probability-Based):
1. Sporadic Left Atrial Myxoma (98%): Pathologically confirmed; perfectly unifies pre-operative microvascular, neurological, and constitutional features.
2. Carney Complex / Familial Myxoma (2%): Low residual probability given young age of presentation; requires ongoing screening for syndromic features.

Prioritized Next Steps & Surveillance:
1. Annual Echocardiography: Perform serial TTE yearly to screen for tumor recurrence or metachronous cardiac lesions.
2. Carney Complex Workup: Evaluate for cutaneous lentigines, perform endocrine screening (serum cortisol, IGF-1, thyroid panel), and offer PRKAR1A genetic testing.
3. Family Screening: Recommend baseline screening echocardiography for first-degree relatives.
4. Cardiology & Neuro Follow-Up: Routine post-operative evaluation to ensure sustained recovery.

Teaching Pearl: Atrial myxoma is the ultimate vasculitis mimic. Always image the heart in patients with suspected vasculitis, embolic phenomena, and normal inflammatory markers or non-specific skin biopsies.

Attending:

Hello Attending Consultant here

Critique: Solid post-resection plan emphasizing surveillance and Carney screen. Overcalls family TTE (reserve for confirmed familial/Carney features). Omit routine neuro f/u absent deficits; prioritize histo review for completeness (e.g., no malignancy).

Top 3 DDx:
1. Sporadic left atrial myxoma (confirmed histo/imaging).
2. Carney complex myxoma (young age; residual 2% risk).
3. Histologic mimic (e.g., myxosarcoma residual; excluded by path).

6 points:
- Annual TTE x5y then q2y for recurrence.
- Carney screen: full skin exam, AM cortisol, IGF-1, TSH; PRKAR1A only if +features.
- No empiric family echo unless syndromic.
- Post-op ASA 81 mg x3mo if residual septal issues.
- Monitor for late emboli/arrhythmia via Holter if sx.
- Document full symptom resolution; d/c IUD if desired.
- Genetic counseling prn.

Expert:

Hello, Expert Clinician here.

Case closed: Benign sporadic left atrial myxoma — the final diagnosis perfectly unified every clue: micro-emboli (splinters, digital lesions, TIA, scotomas), paraneoplastic IL-6–driven constitutional symptoms (fatigue, weight loss, anemia), and exertional triggers. Surgical cure with full symptom resolution is the expected and gratifying outcome.

Why the mimics failed: Vasculitis was excluded by normal ESR/CRP and a bland biopsy; APS was never serologically confirmed; the heart was the source all along.

Key pivots (two): (1) Normal inflammatory markers in apparent "vasculitis" — the first warning; (2) subtle left atrial prominence on CXR — the clue that cracked it.

Most important move (done): Prompt surgical resection — curing embolic, obstructive, and constitutional disease simultaneously.

Residual tasks: Annual echo surveillance (recurrence ~2–5%), Carney complex screen given young age.

Teaching pearl: The "myxoma triad" — embolism, obstruction, constitutional symptoms — mimics vasculitis, endocarditis, and MPN. When systemic symptoms resist an inflammatory diagnosis, image the heart. A $20 chest X-ray preceded $2000 of serology here.

Top 15 Takeaways for Clinicians

  1. Definition of Atrial Myxoma: Atrial myxoma is the most common primary benign cardiac neoplasm, predominantly originating from the fossa ovalis of the left atrial interatrial septum in 75–80% of cases.
  2. The Classic Myxoma Triad: The disease presents with a classic triad: systemic micro-tumor embolization (40%), mechanical intracardiac inflow obstruction (50%), and paraneoplastic constitutional symptoms (50%).
  3. Systemic Vasculitis Mimicry: Left atrial myxomas frequently mimic systemic vasculitis (such as Polyarteritis Nodosa or Antiphospholipid Syndrome) due to peripheral embolic vasculopathy paired with systemic B-symptoms.
  4. Paraneoplastic IL-6 Cytokine Secretion: Tumor cells produce Interleukin-6 (IL-6), driving systemic constitutional symptoms (unintentional weight loss, fatigue, low-grade fever, normocytic anemia, and elevated ESR/CRP).
  5. Diagnostic Significance of Splinter Hemorrhages: Subungual splinter hemorrhages in a young patient without infective endocarditis or trauma are a high-yield physical clue for systemic micro-tumor embolization.
  6. Livedo Racemosa & Digital Ischemia: Peripheral embolization of gelatinous myxoid tumor fragments produces livedo racemosa, palmar mottling, and painful, tender digital ischemic spells.
  7. Exertion/Position-Dependent Visual & Neurological Symptoms: Exertional or posture-induced visual scotomas ("bright flashes") and transient ischemic attacks (TIAs) occur as gravity shifts the pedunculated tumor across the mitral valve.
  8. Normal Inflammatory Markers Red Herring: Systemic vasculitic skin presentations accompanied by normal ESR/CRP and a bland skin biopsy should immediately redirect suspicion to a cardiac embolic source.
  9. Bland Skin Biopsy Pitfall: Dermal skin biopsies of livedoid lesions in atrial myxoma typically reveal sparse non-specific perivascular lymphocytic infiltrates without fibrinoid necrosis or leukocytoclasia.
  10. Role of Transthoracic & Transesophageal Echo (TTE/TEE): TTE/TEE is the definitive diagnostic modality, demonstrating a mobile, pedunculated left atrial mass prolapsing across the mitral valve into the left ventricle during diastole.
  11. Cardiac MRI Tissue Characterization: Cardiac MRI provides precise tissue characterization, distinguishing gelatinous myxomas from thrombi or malignant cardiac sarcomas.
  12. Urgent Surgical Resection Requirement: Diagnosis mandates prompt median sternotomy and complete surgical excision with interatrial septal patch reconstruction to avert stroke or sudden cardiac death.
  13. Pre-Operative Anticoagulation Contraindication: Pre-operative therapeutic anticoagulation is strictly avoided as it can cause tumor fragmentation and increase systemic embolic stroke risk.
  14. Carney Complex Syndromic Screening: Young patients presenting with atrial myxoma should be screened for Carney complex (an autosomal dominant syndrome of cutaneous lentigines, endocrine tumors, and PRKAR1A mutations).
  15. Long-Term Post-Operative Surveillance: Following surgical resection, annual echocardiograms are recommended for at least 4–5 years to monitor for local tumor recurrence (2–5% risk).